Skip to content
Search

Latest Stories

Pharmacy Supervision Practice Group provides recommendations to DHSC to reframe legislation for community pharmacy

Pharmacy Supervision Practice Group, an organisations from across the community pharmacy sector, who have come together to look into the future “supervision” in community pharmacy, have published their final report.

Over the course of nine collaborative and positive workshop-style discussions the Supervision Practice Group aimed to provide recommendations to reframe legislation, regulation and professional standards and guidance to achieve a new vision for community pharmacy.


The group have produced a report which makes several recommendations on the subjects of:

• the legislation relating to “supervision”;

• the temporary absence of the RP from the pharmacy;

• delegation;

• the preparation and assembly of medicines when the RP is not signed in.

The group have provided recommendations on which the Department of and Social Care and the regulators can draft specifically worded revisions to legislation and regulatory standards. These specific legislative and regulatory changes that are proposed by government and regulators will be subject to a full consultation process.

Professional standards and guidance can then be updated to reflect these changes and provide further support to pharmacists and pharmacy technicians.

The group has encouraged all colleagues to read the whole document to understand discussions and reasoning for the recommendations.

Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia and Head of Research Design and Evaluation, NHS Norfolk and Waveney said: “This report is a major step forward for community pharmacy and will enable the sector to work in new ways to support their patients and communities. It is a report that values the contribution of all members of the pharmacy team and provides a platform for the development of a more holistic model of care. I would like to thank all organisations for their commitment to this process and the honesty with which they have approached the discussions and their interaction with me. This report would not have been possible without this commitment to build a positive future for community pharmacy practice.”

AIMp Chief Executive Dr Leyla Hannbeck said: We have been a big advocate for seeking a level playing field for community pharmacists in line with our GP colleagues and this applies to the rules of supervision too. We will be responding to the government consultation in accordance with our vision for a robust, innovative and thriving community pharmacy sector with a skilled workforce that play a key role in the primary care.”

APTUK Vice President Nicola Stockman said: “The vision of community pharmacy practice described in the report will enhance patient access to pharmaceutical services, ensure high levels of patient safety, and enable further development of the community pharmacy team including pharmacy technicians. The consensus arrived at by the Supervision Practice Group should now inform a consultation by the Department of Health and Social Care which we look forward to engaging with.”

CCA Chief Executive Malcolm Harrison said: “All participants agreed on the need for change which is crucial to realising the increasingly clinical future expected of the sector. These changes provide the basis for the greatest evolution in pharmacy practice for 70 years. We want to thank Dr Michael Twigg for chairing the group and the Association of Optometrists for providing its secretariat. The CCA looks forward to responding to the upcoming DHSC consultation on this issue”.

NPA Chair Nick Kaye said: “There is consensus that the physical presence of a pharmacist in the pharmacy is a defining characteristic of community pharmacy – a principle which has been an anchor point for the NPA throughout these talks. We also all agree that changes to current arrangements are necessary to improve access and help pharmacists have the capacity to deliver more face-to-face clinical services. This report means that when the government proceeds to a full consultation on this matter it will have a clear sense of where the consensus sits within the sector.”

PDA Chairman Mark Koziol said: “We want to see pharmacists developing more comprehensive clinical relationships through the delivery of pharmaceutical care in the community pharmacy, to focus on the safety of medicines and to better support patients and the NHS. We have always believed that the physical presence of a pharmacist in a community pharmacy is fundamental to this vision.

"The report published today clearly puts forward a view that the physical presence of a pharmacist in a community pharmacy is essential in providing safe and effective patient care, and while there were differing views on the need for this to be specified in primary legislation, the general point about physical presence was agreed by all. We also welcome that the group agreed that the permitted 2-hour time period for absence should not change, and the PDA will seek to maintain that position. We will now be working with our members to feed into the formal consultation process when that is launched by the government.”

Pharmacy Forum NI Manager Julie Greenfield said: “The Pharmacy Forum NI believe the publication of this report creates a vision and approach that will inform the legislative and regulatory changes now required to deliver future innovation and service development within community pharmacy. Public and patient safety were foremost in our work in addition to enabling full and appropriate use of the skill mix and expertise of the whole pharmacy team.”

RPS President Professor Claire Anderson said: “On behalf of our members, we have been pressing for changes to Supervision legislation for many years. We were pleased to work collaboratively with other pharmacy organisation to feed our views into this statement. The output reflects the views of our Boards across Wales, Scotland and England. The RPS will continue to feed into the consultation process and will keep guiding the professions with trusted standards and advice to support the implementation of any future changes into practice.”

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less